Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20990542 | 0.89 | CETP (0.43) | TSHRCETPNAAAALDH1A1 | |
| SCHEMBL13538272 | 0.84 | TSHR (0.48) | TSHRCETPNAAAPTPN2PTPN1 | |
| SCHEMBL14440190 | 0.84 | TSHR (0.48) | TSHRCETPNAAAPTPN2PTPN1 | |
| SCHEMBL16539706 | 0.82 | TSHR (0.56) | TSHRCETPNAAAPTPN2PTPN1 | |
| SCHEMBL13538269 | 0.82 | TSHR (0.47) | TSHRHTTMEN1KMT2A | |
| SCHEMBL4167079 | 0.82 | CETP (0.62) | TSHRCETPPTPN2PTPN1PTPN6 | |
| SCHEMBL7301581 | 0.81 | TSHR (0.57) | TSHRCETPPOLB | |
| SCHEMBL20958119 | 0.80 | TSHR (0.52) | TSHRCETPNAAAPTPN2PTPN1 | |
| SCHEMBL20958153 | 0.80 | TSHR (0.52) | TSHRCETPNAAAPTPN2PTPN1 | |
| SCHEMBL22724685 | 0.80 | TSHR (0.44) | TSHRCETPNAAAPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1742642-B1 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1558613-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | CCNI, INTS6, CCNE1 | TSHR 3906/4885CETP 4449/4885NAAA 1071/4885 |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | TSHR 4025/4885CETP 4459/4885NAAA 1548/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | TSHR 4025/4885CETP 4459/4885NAAA 1548/4885 |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | TSHR 3915/4885CETP 4657/4885NAAA 918/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | TSHR 4778/4885CETP 3027/4885NAAA 420/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | TSHR 4778/4885CETP 3027/4885NAAA 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.